Biocon Biologics to receive $150 million from Goldman Sachs against convertible debentures

“The Board of its (Biocon’s) subsidiary Biocon Biologics has approved a Rs 1,125 Crore ($150 million) capital injection from Goldman Sachs. As per the terms of the proposed agreement, Goldman Sachs will be issued optionally convertible debentures at a post money equity valuation of $ 3.94 Billion,” said Biocon in a press release.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3p63kdL
via IFTTT